PT-141 (Bremelanotide)
PT-141, also known by its generic clinical name Bremelanotide, is a synthetic peptide derived from alpha-melanocyte-stimulating hormone (α-MSH). It has undergone clinical trials as a potential treatment for hypoactive sexual desire disorder (HSDD) in both men and women, as well as for acute hemorrhage. It acts as an agonist for the melanocortin-4 receptor (MC4R) and the melanocortin-1 receptor (MC1R). Research indicates that it has the ability to enhance sexual arousal and stimulate the immune system.
PEPTIDES LIST
- Adipotide (FTPP)
- AICAR
- AOD9604
- ARA-290
- B7-33
- BPC-157
- Bronchogen
- Cagrisema
- Cagrilintides
- Cardiogen
- Cartalax
- Cerebrolysin (215mg/ml, 10ml)
- Chonluten
- CJC-1295 DAC
- Cortagen
- DSIP
- Epithalon (Epitalon)
- Follistatin-315
- Follistatin-344
- FOXO4-DRI
- GHK-Cu (Copper Peptide)
- GHK Basic
- GHRP-2
- GHRP-6
- GHRH (GH-Releasing Hormone)
- Glutathione
- Gonadorelin (GnRH)
- GLP2 & GLP3
- hGH Fragment 176-191
- Hexarelin
- Humanin
- Ipamorelin
- Kisspeptin-10
- KPV (ACTH (11-13) alpha-MSH)
- Liraglutide (GLP-1 Analogue)
- Livagen
- LL-37 (CAP-18)
- Melanotan 2 (Melanotan II)
- Mezdutide
- MGF (C-terminal)
- ModGRF 1-29 (CJC-1295 No DAC)
- MK-677 (Ibutamoren)
- MOTS-c
- N-Acetyl Epithalon Amidate
- N-Acetyl Selank Amidate
- N-Acetyl Semax Amidate
- NAD+
- Ovagen
- Oxytocin+
- Pancragen
- PE-22-28
- PEG-MGF (Pegylated MGF)
- Pinealon
- PNC-27
- Prostamax
- PT-141 (Bremelanotide)
- P21 (P021)
- Retatrutide
- Snap8
- Tesa_Ipa_Blend
- Triblend
- Selank
- Semaglutide (GLP-1 Analogue)
- Semax
- Sermorelin
- SS-31
- Survodutide
- TB-500
- Tesamorelin
- Testagen
- Thymagen
- Thyrotropin-TRH
- Tirzepatide
- Triptorelin
- Vesugenas
- Vesilute
- Vilon
- VIP (Vasoactive Intestinal Peptide)
- GLP2
- GLP3
- Klow
- Klow8
- SLU-PP-332
- BAM-15
- Orforglipron
- Noopept
- 9-Me-BC
- Methylene Blue
- Lemon Bottle
The source describes PT-141 (bremelanotide) dosing as per-dose guidance (not a fixed weekly ramp). Typical dosing is described as around 1 mg per dose, with the option to increase up to 4 mg based on response and goal.
| Protocol Item | Guidance (As Listed) |
|---|---|
| Typical Dose | ~1 mg per dose (can be increased up to 4 mg) |
| Timing | Best taken 45–60 minutes before intercourse |
| Max Frequency | One dose per 72 hours at most (more can contribute to receptor desensitization) |
| Duration | Effects may last 24–72 hours |
Caution & Contraindications:
Caution:
• May cause flushing, headaches, nausea, vomiting, and dizziness
• Use caution in individuals with cardiovascular disease and/or uncontrolled high blood pressure
Contraindications:
• Do not combine with other PDE-5 inhibitors (e.g., Cialis, Viagra, etc.)
Reconstitution Options (Vial Format):
• 3 mg
• 10 mg
Reconstitution (General Handling):
• Use sterile technique and sanitize the vial stopper before each access.
• Add diluent slowly along the vial wall to minimize foaming.
• Gently swirl/roll until fully dissolved (avoid vigorous shaking).
• Store as directed on the product label/spec sheet and protect from light as applicable.
Sequence: Ac-Nle-Asp(1)-His-D-Phe-Arg-Trp-Lys(1)
Molecular Formula: C50H68N14O10
Molecular Weight: 1025.182 g/mol
PubChem CID: 9941379
CAS Number: 189691-06-3
PT-141, through its stimulation of the MC-4R, plays a unique role in promoting sexual arousal. Studies in mice have demonstrated that activation of the MC-4R leads to sexual arousal and increased copulation in both male and female rodents. Unlike medications like Viagra, which primarily address issues related to blood flow, Bremelanotide operates through a different mechanism, making it a potential treatment for sexual arousal disorders in both men and women stemming from various causes.
In a study involving men with erectile dysfunction (ED) who did not respond to sildenafil (Viagra), approximately one-third of them experienced sufficient erection for sexual intercourse when treated with Bremelanotide in the form of a nasal spray. Furthermore, the trial showed a strong dose-dependent response, indicating the effectiveness of Bremelanotide in specific cases. This suggests that Bremelanotide may offer a viable option for addressing ED in situations where sildenafil has proven ineffective and may shed light on central causes of hypoactive sexual desire.
PT-141 and Female Sexual Dysfunction PT-141, although showing promise in clinical trials for treating Hypoactive Sexual Desire Disorder (HSDD) in women by increasing satisfying sexual events and reducing sexual distress, was halted before approval. This decision has left experts in female sexual dysfunction (FSD) disappointed, citing a lack of clear trial endpoints and societal biases as major obstacles to approval. They call for increased attention to women's sexual health and the establishment of firm FDA guidelines for evaluating such therapies.
PT-141 and Hemorrhage In 2009, PT-141 was slightly modified and explored as a potential treatment for hemorrhagic shock. Its binding to both MC-1R and MC-4R receptors helps reduce ischemia and protect tissues in cases of hypovolemic (hemorrhagic) shock when administered intravenously. Notably, this version of PT-141, referred to as PL-6983, demonstrated minimal side effects during phase IIb trials.
PT-141 is associated with minimal side effects and exhibits favorable bioavailability when administered subcutaneously or orally in mice. However, it's crucial to emphasize that the dosage per kilogram in mice does not directly translate to humans. Any PT-141 purchase from Peptide Sciences is strictly intended for educational and scientific research purposes and is not intended for human consumption. Only licensed researchers should consider acquiring PT-141 for their studies.
Article Author:
The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from https://case.edu/medicine/Case Western Reserve University School of Medicine and a B.S. in molecular biology.
Case Western Reserve University School of Medicine
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
The product information featured on this website pertains exclusively to in-vitro studies. In-vitro studies, also known as 'in glass' studies, are conducted outside of living organisms. It's important to emphasize that these products do not constitute medicines or drugs and have not received FDA approval for the prevention, treatment, or cure of any medical conditions, ailments, or diseases. It is crucial to note that the introduction of these products into the bodies of humans or animals is strictly prohibited by law.
THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.
